WG-1025

N/A

Report date: 2024/11/07 14:09:27

Base Information

Drug NameWG-1025
Drug Alias NameWG1025WG-1025
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Herpes simplex virus vector > HSV-1 vector
Mechanisms of ActionCOL7A1 gene transference
TargetsCollagen alpha-1(VII) chain
Therapy Area/IndicationsEpidermolysis Bullosa Dystrophica
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Weiyuan Likang Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Weiyuan Likang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsEpidermolysis Bullosa Dystrophica
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A